Soligenix (SNGX) Competitors $1.25 -0.11 (-8.09%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.28 +0.03 (+2.80%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. CTXR, PRPH, CASI, RLYB, DRRX, LPCN, PMN, GELS, ASBP, and ALLRShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Citius Pharmaceuticals (CTXR), ProPhase Labs (PRPH), CASI Pharmaceuticals (CASI), Rallybio (RLYB), DURECT (DRRX), Lipocine (LPCN), Promis Neurosciences (PMN), Gelteq (GELS), Aspire Biopharma (ASBP), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors Citius Pharmaceuticals ProPhase Labs CASI Pharmaceuticals Rallybio DURECT Lipocine Promis Neurosciences Gelteq Aspire Biopharma Allarity Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Is CTXR or SNGX more profitable? Citius Pharmaceuticals' return on equity of -58.63% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -58.63% -37.67% Soligenix N/A -223.89%-103.50% Which has more risk and volatility, CTXR or SNGX? Citius Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Which has stronger valuation & earnings, CTXR or SNGX? Soligenix has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/ASoligenix$120K33.96-$8.27M-$4.29-0.29 Do institutionals & insiders believe in CTXR or SNGX? 16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer CTXR or SNGX? Citius Pharmaceuticals currently has a consensus price target of $53.00, indicating a potential upside of 3,151.53%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Soligenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CTXR or SNGX? In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Soligenix. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 2 mentions for Soligenix. Soligenix's average media sentiment score of 0.62 beat Citius Pharmaceuticals' score of 0.31 indicating that Soligenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCitius Pharmaceuticals beats Soligenix on 8 of the 12 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.44M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.2920.2228.5419.58Price / Sales33.96299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.767.568.145.54Net Income-$8.27M-$55.11M$3.24B$257.73M7 Day PerformanceN/A3.81%0.18%-0.08%1 Month Performance-30.56%11.60%5.96%8.09%1 Year Performance-82.61%-2.11%26.24%13.02% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix0.9699 of 5 stars$1.25-8.1%N/A-81.8%$4.44M$120K-0.2920Gap DownCTXRCitius Pharmaceuticals3.0216 of 5 stars$1.67+7.1%$53.00+3,073.7%-91.5%$17.75MN/A0.0020Gap UpPRPHProPhase Labs0.5386 of 5 stars$0.43+0.4%N/A-87.1%$17.66M$5.85M-0.34130CASICASI Pharmaceuticals4.2313 of 5 stars$1.43+2.1%$4.00+179.7%-79.2%$17.59M$31.37M-0.56180Positive NewsGap DownRLYBRallybio2.6262 of 5 stars$0.42+3.4%$10.00+2,281.0%-69.1%$17.48M$848K-0.3940Gap UpDRRXDURECT1.2114 of 5 stars$0.56-10.5%N/A-60.7%$17.39M$1.86M-3.7380Positive NewsGap DownLPCNLipocine3.0108 of 5 stars$3.20-2.1%$9.00+181.3%-58.0%$17.12M$3.67M-3.1410PMNPromis Neurosciences3.0853 of 5 stars$0.52+33.2%$4.33+733.3%-79.3%$17.00MN/A-10.405News CoverageAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeGELSGelteqN/A$1.76-2.8%N/AN/A$16.61M$100K0.00N/AGap DownASBPAspire BiopharmaN/A$0.33+0.3%N/AN/A$16.39MN/A0.00N/AALLRAllarity Therapeutics0.5806 of 5 stars$1.05+4.0%N/A-83.1%$15.83MN/A0.0010News Coverage Related Companies and Tools Related Companies Citius Pharmaceuticals Competitors ProPhase Labs Competitors CASI Pharmaceuticals Competitors Rallybio Competitors DURECT Competitors Lipocine Competitors Promis Neurosciences Competitors Gelteq Competitors Aspire Biopharma Competitors Allarity Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNGX Stock Alerts